Monotherapy in treatment of partial onset seizures w/ or w/o secondary generalization in patients from 16 yr w/ newly diagnosed epilepsy. Adjunctive treatment of partial onset seizures w/ or w/o secondary generalisation in adults & childn from 4 yr w/ epilepsy; myoclonic seizures in adults & adolescents from 12 yr w/ juvenile myoclonic epilepsy; primary generalized tonic-clonic seizures in adults & childn from 12 yr w/ idiopathic generalized epilepsy. IV: Alternative when PO is temporarily not feasible.
MonotherapyAdult & adolescent from 16 yr Initially 250 mg bd, may be increased to 500 mg bd after 2 wk then further increased by 250 mg bd every 2 wk. Max: 1,500 mg bd. Add-on therapyAdult ≥18 yr & adolescent 12-17 yr, ≥50 kg Initially 500 mg bd, may be increased up to 1,500 mg bd. Dose changes can be made in 500 mg bd increases or decreases every 2-4 wk. Childn 4-11 yr & adolescent 12-17 yr, 25-50 kg Initially 10 mg/kg bd, may be increased up to 30 mg/kg bd. Dose changes should not exceed 10 mg/kg bd increases or decreases every 2 wk. Childn ≥50 kg Adult dose.
Monitor for signs of depression &/or suicidal ideation & behaviours; developing psychiatric signs suggesting important mood &/or personality changes. Perform CBC count during therapy. Avoid abrupt w/drawal. May affect ability to drive & use machines. Acute kidney injury. Renal & severe hepatic impairment. Women of childbearing potential. Pregnancy. Not recommended during lactation. Elderly ≥65 yr. Monotherapy treatment in childn & adolescents <16 yr. Tab: Not to be used in childn <6 yr. IV: Patients on controlled Na diet.
Sign Out
